Human responses to two decavalent rhinovirus vaccines.
Two formalin-inactivated, decavalent rhinovirus vaccines were tested in humans for acceptability and antigenicity. Infectivity titers of the vaccine antigens were low and ranged from 10(1.5) to 10(5.5) 50% tissue culture infective doses/ml. There were minimal or no side effects to either vaccine. The first inoculation of one vaccine produced antigenic responses to 30% of the administered antigens. Limited testing for heterologous antibody responses to nonvaccine antigens showed scattered responses. These findings suggest that potent multivalent rhinovirus vaccines containing antigens selected for cross-reactivity should be tested in an attempt to develop practical control measures for rhinoviruses.
D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis; D003429:Cross Reactions; D006801:Humans; D009500:Neutralization Tests; D012141:Respiratory Tract Infections / Q000517:prevention & control; D012229:Rhinovirus; D014611:Vaccination; D014765:Viral Vaccines; D014777:Virus Diseases / Q000276:immunology / Q000517:prevention & control*
D000914:Antibodies, Viral; D014765:Viral Vaccines